Our Mission

Aleta’s mission is to create cell therapeutics that provide robust and durable clinical benefit for patients suffering from advanced hematologic cancers and refractory solid tumors. Aleta’s CAR-T Engager technology incorporates potent multi-antigen targeting, optimal T cell fitness, and persistence to aggressively attack cancers. We use this technology to build programs that solve specific clinical issues, including cell therapy relapses due to antigen loss and the challenge of overcoming solid tumor heterogeneity. Our lead development program has won landmark clinical support from Cancer Research UK and will enter Phase1/2 trials in 2022.

Our Science

With our CAR-T Engager platform, we are building treatments to enhance cell therapies. Our lead candidate, ALETA-001, is focused on eliminating CD19 CAR-T relapses.

Latest News

Aleta Biotherapeutics and Cancer Research UK collaborate to advance blood cancer therapy into the clinic

Aleta Biotherapeutics today announced a poster presentation at the 63rd American Society of Hematology (ASH)
Annual Meeting, to be held in Atlanta, Georgia and in a virtual platform on December 11-14, 2021.

The presentation will feature preclinical data that support the upcoming Phase 1/2 clinical trial of ALETA-001 being run in collaboration with Cancer Research UK. Extensive preclinical in vitro modeling demonstrated that ALETA-001 specifically binds to CD20-positive/CD19 negative lymphoma cells.

Get In Touch

Send message